Results 31 to 40 of about 141,567 (268)

Lymphatic Filariasis: A Systematic Review on Morbidity and Its Repercussions in Countries in the Americas

International Journal of Environmental Research and Public Health, 2021
The Global Program to Eliminate Lymphatic Filariasis (GPELF) is a program that aims to eliminate lymphatic filariasis by 2030. The GPELF strategy is based on interrupting transmission using mass drug administration (MDA) and, in parallel, managing ...
Z. Medeiros, A. V. B. Vieira, A. Xavier, G. Bezerra, M. D. F. Lopes, C. Bonfim, A. Aguiar-Santos   +6 more
semanticscholar   +1 more source

Recombinant antigens used as diagnostic tools for lymphatic filariasis

Parasites & Vectors, 2021
Lymphatic filariasis (LF) is a parasitic disease caused by the worms Wuchereria bancrofti, Brugia malayi, or Brugia timori. It is a tropical and subtropical illness that affects approximately 67 million people worldwide and that still requires better ...
A. Pastor, Maressa Rhuama Silva, Wagner José Tenório dos Santos, Tamisa Rego, E. Brandão, O. P. de-Melo-Neto, A. Rocha   +6 more
semanticscholar   +1 more source

Individual efficacy and community impact of ivermectin, diethylcarbamazine and albendazole mass drug administration for lymphatic filariasis control in Fiji: a cluster randomised trial.

Clinical Infectious Diseases, 2021
BACKGROUND Bancroftian filariasis remains endemic in Fiji despite over 10 years of mass drug administration (MDA) using diethylcarbamazine and albendazole (DA).
Myra Hardy, Josaia Samuela, M. Kama, M. Tuicakau, L. Romani, M. Whitfeld, C. King, G. Weil, A. Grobler, L. Robinson, J. Kaldor, A. Steer   +11 more
semanticscholar   +1 more source

Albendazole for lymphatic filariasis [PDF]

Cochrane Database of Systematic Reviews, 2004
Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.To assess the effects of albendazole on patients or populations with filarial infection, and on morbidity in patients with filarial infection; and to assess the frequency of adverse events ...
Critchley J, Addiss D, Ejere H, Gamble C, Garner P, Gelband H   +5 more
openaire   +6 more sources

Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor–mediated lymphangiogenesis

Journal of Clinical Investigation, 2021
Lymphatic filariasis is the major global cause of nonhereditary lymphedema. We demonstrate that the filarial nematode Brugia malayi induced lymphatic remodeling and impaired lymphatic drainage following parasitism of limb lymphatics in a mouse model ...
Julio Furlong-Silva, Stephen Cross, A. Marriott, N. Pionnier, J. Archer, A. Steven, Stefan Merker, M. Mack, Young-Kwon Hong, M. Taylor, J. Turner   +10 more
semanticscholar   +1 more source

Sensitivity analysis and parameters estimation for the transmission of lymphatic filariasis

Heliyon, 2023
Lymphatic filariasis is a neglected tropical disease which poses public health concern and socio-economic challenges in developing and low-income countries.
Mussa A. Stephano, Maranya M. Mayengo, Jacob I. Irunde, Dmitry Kuznetsov   +3 more
doaj   +1 more source

Scaling-up filariasis lymphoedema management into the primary health care system in Kerala State, Southern India: a case study in healthcare equity

Infectious Diseases of Poverty, 2022
Background Lymphatic filariasis (LF) remains one of the world’s most debilitating parasitic infections and is a major contributor to poor health in many endemic countries. The provision of continuing care for all those affected by LF and its consequences
Suma T. Krishnasastry, Charles D. Mackenzie, Rajeev Sadanandan   +2 more
doaj   +1 more source

Sociodemographic characteristics as predictors of knowledge regarding mode of transmission of Lymphatic Filariasis among population of Nepal.

PLOS Global Public Health, 2022
IntroductionThe majority of the districts of Nepal (63 out of 77) were detected as prevalent of Lymphatic Filariasis (LF), with an average prevalence of 13 percent ranging from less than one to 39 percent in Nepal. Despite people's ignorance about the LF,
Ramesh Adhikari, Devaraj Acharya, Aakriti Wagle   +2 more
doaj   +2 more sources

India can consider integration of three eliminable disease control programmes on malaria, lymphatic filariasis, and visceral leishmaniasis

PLoS Pathogens, 2021
Disease-specific programmes (also called vertical, stand-alone, categorical, or free-standing) are directed, supervised and executed via single vehicle using dedicated health workers.
M. Rahi, Rini Chaturvedi, P. Das, Amit Sharma   +3 more
semanticscholar   +1 more source

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach [PDF]

, 2019
BACKGROUND: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs.
Dubray, Christine, Fischer, Peter U, Goss, Charles W, Hardy, Myra, Jambulingam, Purushothaman, King, Christopher L, Laman, Moses, Lemoine, Jean Frantz, O\u27Brian, Katiuscia, Robinson, Leanne J, Samuela, Josaia, Schechtman, Kenneth B, Subramanian, Swaminathan, Supali, Taniawati, Weil, Gary J   +14 more
core   +2 more sources